Company intelligence / Profile preview

Therion Biologics

Cambridge, Massachusetts, United Statesbiospace.com ↗

Ownership: Private
Development stage: Other

Overview

Therion Biologics developed poxvirus-based therapeutic vaccines targeting various cancers. Its lead programs were PANVAC-VF (Phase III, pancreatic cancer) and PROSTVAC-VF (Phase II, prostate cancer). The company also had clinical-stage programs in colorectal, ovarian, breast, and lung cancers. Clinical data from pivotal trials were expected in the mid-to-late 2000s but the company ceased operations before commercialization.

Therapeutic areas: Oncology
Modalities: Recombinant vector vaccineTherapeutic vaccineVaccine
Industry: Biotech

Drug pipeline

8 assets

PANVAC-VF

7 more assets in the full pipeline.

Request access →

Partnerships

Aventis Pasteur [now Sanofi Pasteur]National Cancer Institute [NCI]Network of clinical institutions [academic/hospital partners not individually listed]

Beyond the preview

Go deeper on Therion Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Therion Biologics.

Explore the full profile